Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments
In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments are not available, indirect comparisons can be of interest. Reconstruction o...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Hematology Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2038-8330/15/1/6 |
| _version_ | 1797611492370022400 |
|---|---|
| author | Luca Cancanelli Melania Rivano Lorenzo Di Spazio Marco Chiumente Daniele Mengato Andrea Messori |
| author_facet | Luca Cancanelli Melania Rivano Lorenzo Di Spazio Marco Chiumente Daniele Mengato Andrea Messori |
| author_sort | Luca Cancanelli |
| collection | DOAJ |
| description | In recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments are not available, indirect comparisons can be of interest. Reconstruction of individual patient data from Kaplan-Meier graphs (e.g., according to the Shiny method) has been the subject of numerous reports that have fully validated their performance. In the present systematic review, we evaluated six treatments proposed for RRMM, including two CAR-T products (ciltacabtagene autoleucel and idecabtagene vicleucel) and four treatments not based on a CAR-T (melflufen plus dexamethasone, isatuximab plus dexamethasone, selinexor, and belantamab). The endpoint was overall survival (OS). Our results showed statistically significant differences in OS across these treatments. In particular, ciltacabtagene autoleucel showed better OS than idecabtagene vicleucel. As regards non-CAR-T treatments, the ranking in OS was headed by isatuximab plus dexamethasone, followed by belantamab, selinexor, and melflufen plus dexamethasone. In conclusion, while the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies. |
| first_indexed | 2024-03-11T06:29:33Z |
| format | Article |
| id | doaj.art-e66bd5262cf34d22a212584e1c223575 |
| institution | Directory Open Access Journal |
| issn | 2038-8330 |
| language | English |
| last_indexed | 2024-03-11T06:29:33Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Hematology Reports |
| spelling | doaj.art-e66bd5262cf34d22a212584e1c2235752023-11-17T11:22:30ZengMDPI AGHematology Reports2038-83302023-01-01151576510.3390/hematolrep15010006Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New TreatmentsLuca Cancanelli0Melania Rivano1Lorenzo Di Spazio2Marco Chiumente3Daniele Mengato4Andrea Messori5Hospital Pharmacy Department, Azienda Ulss 2 Marca Trevigiana, Castelfranco Veneto, 31033 Treviso, ItalyHospital Pharmacy Department, Binaghi Hospital, 09126 Cagliari, ItalyHospital Pharmacy Department, S. Chiara Hospital, 38122 Trento, ItalyScientific Direction, Società Italiana di Farmacia Clinica e Terapia (SIFaCT), 20159 Milan, ItalyHospital Pharmacy Department, Azienda Ospedale, Università of Padova, 35122 Padova, ItalyHTA Unit, Regional Health Service, 50136 Firenze, ItalyIn recent years, new treatments have been studied for relapsed-refractory multiple myeloma (RRMM), including two CAR-T products and a variety of non-CAR-T agents. Since direct comparisons between these innovative treatments are not available, indirect comparisons can be of interest. Reconstruction of individual patient data from Kaplan-Meier graphs (e.g., according to the Shiny method) has been the subject of numerous reports that have fully validated their performance. In the present systematic review, we evaluated six treatments proposed for RRMM, including two CAR-T products (ciltacabtagene autoleucel and idecabtagene vicleucel) and four treatments not based on a CAR-T (melflufen plus dexamethasone, isatuximab plus dexamethasone, selinexor, and belantamab). The endpoint was overall survival (OS). Our results showed statistically significant differences in OS across these treatments. In particular, ciltacabtagene autoleucel showed better OS than idecabtagene vicleucel. As regards non-CAR-T treatments, the ranking in OS was headed by isatuximab plus dexamethasone, followed by belantamab, selinexor, and melflufen plus dexamethasone. In conclusion, while the Shiny method has confirmed its validity in reconstructing individual patient data, our indirect comparisons have offered some original clues to interpret the results of OS published in these studies.https://www.mdpi.com/2038-8330/15/1/6relapsed-refractory multiple myelomaoverall survivalCAR-Tnon-CAR-T agents |
| spellingShingle | Luca Cancanelli Melania Rivano Lorenzo Di Spazio Marco Chiumente Daniele Mengato Andrea Messori Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments Hematology Reports relapsed-refractory multiple myeloma overall survival CAR-T non-CAR-T agents |
| title | Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments |
| title_full | Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments |
| title_fullStr | Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments |
| title_full_unstemmed | Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments |
| title_short | Survival in Patients with Relapsed-Refractory Multiple Myeloma: Indirect Comparison of Six New Treatments |
| title_sort | survival in patients with relapsed refractory multiple myeloma indirect comparison of six new treatments |
| topic | relapsed-refractory multiple myeloma overall survival CAR-T non-CAR-T agents |
| url | https://www.mdpi.com/2038-8330/15/1/6 |
| work_keys_str_mv | AT lucacancanelli survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments AT melaniarivano survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments AT lorenzodispazio survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments AT marcochiumente survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments AT danielemengato survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments AT andreamessori survivalinpatientswithrelapsedrefractorymultiplemyelomaindirectcomparisonofsixnewtreatments |